You are here

Home » Content

HEMODİYALİZ YETERLİLİĞİ İLE KOMORBİD FAKTÖRLER ARASINDAKİ İLİŞKİ

THE RELATIONSHIP BETWEEN HEMODIALYSIS ADEQUACY AND CO-MORBID FACTORS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Dialysis adequacy is described as reducing mortality ayid morbidity rates besides improving the uremic symptoms of patients. In this study, it was aimed to assess the relationship between dialysis adequacy determined by urea kinetic model (UKM) and co-morbid factors. Daily Kt/V (Kti/V) value was determined in 52 hemodialysis (HD)patients. A morbidity score (MORS) was created by scoring seventeen clinical, biochemical and radiological parameters as one or zero. Daily Kt/V(Kti/V) of HD patients was found 0.41. The Kti/V value of HD patients was found to be 19.6 % lower than the value proposed by NKF-DOQI. There was a positive correlation between Kti/ V and normalized protein catabolic rate (nPCR) (r=0.814, p<0.01) and a negative correlation between Kti/V and MORS(r=-0.314, p<0.05) while there was no correlation between Kti/V and the other individual parameters of MORS. We concluded that, in assessing the adequacy of dialysis, morbid factors were efficient as well as UKM and it could have been a mistake to use only Kt/V for determining dialysis adequacy.
Bookmark/Search this post with
Abstract (Original Language): 
Diyaliz yeterliliği, hastanın üremik belirtilerini gidermek yanında, morbidite ve mortalite oranlarının azaltılması olarak tanımlanmaktadır. Bu çalışmada üre kinetik model (ÜKM) ile saptanmış olan diyaliz yeterliliğinin, morbid faktörlerle ilişkisinin araştırılması amaçlanmıştır. Elli iki hemodiyaliz (HD) hastasının günlük eşdeğer Kt/V (Kti/V) değeri tespit edilmiştir. Onyedi adet klinik, biyokimyasal ve radyolojik parametreye 0 ya da 1 puan verilerek bir morbidite skoru (MORS) oluşturulmuştur. Kti/V değeri HD hastaları için 0.41 bulunmuştur. HD hastalarında saptanan Kti/V değerinin NKF-DOQI kriterlerine göre, istenenden % 19.6 daha düşük olduğu saptanmıştır. HD hastalarında Kti/V ile normalleştirilmiş protein katabolizma hızı (NPKH) değerinin kuvvetli korelasyon (r =0.814, p <0.01), MORS'un ters korelasyon gösterdiği (r=-0.314, p <0.05) saptanmış; MORS'u oluşturan parametrelerin herbiri ile Kti /V değeri arasında korelasyon olmadığı belirlenmiştir. Çalışmamızda diyaliz yeterliliğinin belirlenmesinde ÜKM yanında morbid durumların da etkili olduğu, tek başına KtfV ile sonuca ulaşmanın hatalı değerlendirmelere yol açabileceği sonucuna ulaşılmıştır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_375.pdf
  • 1
44-51
  • Turkish

REFERENCES

References: 

1. Lowrie EG and Laird NM[Eds]:The National Cooperative Dialysis Study (NCDS).Kidney Int 1983;23 [Suppl.13]: 1-123.
2. Beto JA, Bansal VK, Ing TS, Daugirdas JT, for the Council on Renal Nutrition National. Research Question Collaborative Study Group.: Variation in blood sample collection for determination of hemodialysis adequacy. AJKD 1998; 31:135-141.
3. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC,
Vanel T, Laurent G. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286-1291.
4. Covic A, Goldsmith DJA, Hill K, Venning MC, Ackrill P.
Urea kinetic modelling-Are any of the "bedside" Kt/V formulae reliable enough? Nephrol Dial Transplant 1998; 13:31-38.
5. Depner T, Beck G, Daugirdas J, Kusek J, Eknoyan G: Lessons from the hemodialysis (HEMO) study: An improved measure of the actual hemodialysis dose. AJKD 1999;33:142-149.
SO
6. Gotch FA and Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study. Kidney Int 1985; 28:526-534.
7. National Kidney Foundation -Dialysis Outcomes Quality Initiative (NKF-DOQI) Hemodialysis Adequacy Work Group: Clinical Practice Guidelines For Hemodialysis Adequacy. AJKD 1997; 30:38-42.
8. Depner TA, Greene T, Gotch FA, Daugirdas JT, Keshaviah PR, Star RA: The Hemodialysis Study Group: Imprecision of the hemodialysis dose when measured directly from urea removal. Kidney Int 1999;
55: 635-647.
9. Hakim RM, Breyer J, Nuhad I, Schulman G: Effects of dose of dialysis on morbidity and mortality. AJKD 1994; 23(5):661-669.
10. Depner TA:Standarts for dialysis adequacy. Seminars
in Dialysis 1991; 4:245-252.
11. Lindsay RM, Spanner E, Heidenheim RP, Lefebvre JM, Hodsman A, Baird J, Allison MEM: Which comes first,
Kt/V or PCR-chicken or egg? Kidney Int 1992; 42(Suppl.
38):32-36.
12. Leavy SF, Strawdermann RL, Jones CA, Port FK, Held PJ: Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. AJKD 1998; 31: 997¬1006.
13. Lowrie EG and Lew NL: Death risk in haemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences
between facilities. AJKD 1990; 15:458-482.
14. Tattersall J, Greenwood R, Farrington K: Urea kinetics and when to commence dialysis. Am J Nephrol 1995; 15:283¬289.
15. Collins AJ, Ma JZ,Xia H, Ebben J: Patient survival is associated with hematocrit level. Am Soc Nephrol 1997; 8 (Abstr):190a.
16. Madore F, Bridges K, Lew N, Lowrie E, Lazarus JM, Owen F. Anemia in hemodialysis patients: variables impacting this outcome predictor. JASN 1997; 8:1921¬1929.
17. Hannah R, Levin NW, London R, Osheroff WJ: Renal
disease in the managed care setting: Selection and monitoring of outcome criteria. AJKD 1999; 33 (Suppl-1):
10-16.
17a. Cannata-Andia J, Passlick-Deetjen J, Ritz E: Management of the renal patient: Expert's recommendations and clinical algorithms on renal osteodystrophy. Pabst Science
Publishers, Berlin, 2001 ;pp:104-105.
18. MingardiG, The DIA-QOL Group: From the development to the clinical application of a questionnaire on the quality of life in dialysis. The experience of the Italian Collaborative DIA-QOL( Dialysis-Quality of Life ) Group. Nephrol Dial Transplant 1998; 13 (Suppl.l) :70-75.
19. Held PJ, Akiba T, Stearns NS, Marumo F, Turenne MN,
Maeda K, Port FK: Patient survival in Japan and the US for middle-aged dialysis patients, 1980-1990; in Friedman EA, Hingham MA(eds):Death on Dialysis. Dordrecht, Kluwer. 1994, pp: 13-23.
20. Held PJ, Brunner FB, Odaka M,Garcia JR, Port FK, Gaylin DS: Five-year survival for end-stage renal disease patients in the United States. Europe, and Japan, 1982 - 1987.
AJKD 1990; 15: 451-457.
21. Disney Aps. Australia and New Zealand Dialysis and Transplant. Report Registry ,1995; p: 135.
22. Mallick NP.Short CD,Patel M: Abstracts of renal association. Nephrol Dial Trans 1996; 11: 1694.
23. Frankensfield DL, Mcclellan WM, Helgerson SD, Lowrie EG,Rocco MV,0wen WF:Relationship between urea reduction ratio, demographic characteristics, and body weight for patients in the 1996 National ESRD Core
Indicators Project. AJKD 1996; 33:584-591.
24. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE,
Daugirdas JT, Bloembergen WE, Greer JW, Hakim RM: The dose of hemodialysis and patient mortality. Kidney Int 1996;50:550-556.
25. Mcclellan WM, Soucie JM, Flanders WD: Mortality in
end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. JASN 1998; 9:1940-1947.
26. Valderrabano F, Perez-Garcia R, Junco E: How to prescribe optimal haemodialysis. Nephrol Dial Transplant 1996; 11
(Suppl. 2): 60-67.
27. Bergström J: Nutrition and adequacy of dialysis in hemodialysis patient. Kidney Int 1993; 43 (Suppl.41): 261-267.
28. Owen WFII, Lew NL, Liu Y, Lowrie EG, Lazarus JM:
The urea reduction ratio and serum serum albumin concentration as predictors of mortality in patients
undergoing hemodialysis. NEJM 1993;329:1001-1006.
29. Schleifer CR, Snyder S, Jones K: The influence of urea kinetic modeling on gross mortality in hemodialysis. JASN
1991; 2:349.
30. Raine AEG: Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoetin therapy. Lancet 1988; 1: 97-100.
31. Blake PG, Balaskas EV, Izzat S, Oreopoulos DG: Is total creatinine clearance a good predictor of clinical outcomes in continuous ambulatory peritoneal dialysis? Peritoneal
Dialysis International 1992 ; 12:353-358.
32. Valderrabano F: Weekly duration of dialysis treatment-does it matter for survival. Nephrol Djal Transplant
1996 ; H:Editorial Comments: 569-572.
33. Owen WF: Status of hemodialysis adequacy in the united states: Does it account for improved patient
survival. AJKD 1998 ; 32(Suppl. 4):39-43.

Thank you for copying data from http://www.arastirmax.com